Selective targeting BMP2 and 4 in SMAD4 negative esophageal adenocarcinoma inhibits tumor growth and aggressiveness in preclinical models

• Published in: Cellular oncology (Dordrecht) Vol. 45; no. 4; pp. 639 - 658
• Main Authors: Li, Shulin, Hoefnagel, Sanne J. M., Read, Matthew, Meijer, Sybren, van Berge Henegouwen, Mark I., Gisbertz, Suzanne S., Bonora, Elena, Liu, David S. H., Phillips, Wayne A., Calpe, Silvia, Correia, Ana C. P., Sancho-Serra, Maria D. C., Mattioli, Sandro, Krishnadath, Kausilia K.
• Format: Journal Article
• Language: English
• Published: Dordrecht Springer Netherlands 01.08.2022; Springer Nature B.V
• Subjects: Adenocarcinoma; Adenocarcinoma - pathology; Animals; Biomedical and Life Sciences; Biomedicine; Bone morphogenetic protein 2; Bone Morphogenetic Protein 2 - metabolism; Bone morphogenetic protein 4; Bone Morphogenetic Protein 4 - metabolism; Bone morphogenetic proteins; Cancer; Cancer Research; Cisplatin; Esophageal Neoplasms - pathology; Esophagus; Gene set enrichment analysis; Hedgehog protein; Hedgehog Proteins - metabolism; Humans; MAP kinase; Mice; Oncology; Original; Original Article; Pathology; Patients; Phenotypes; Signal transduction; Smad4 protein; Smad4 Protein - metabolism; Tumor cells; Xenografts; BMP4; SMAD4; BMP2; anti-BMP antibodies, VHHs; esophageal adenocarcinoma
• ISSN: 2211-3428; 2211-3436; 2211-3436
• DOI: 10.1007/s13402-022-00689-2

Purpose Abnormalities within the Sonic Hedgehog (SHH), Bone Morphogenetic Protein (BMP) and SMAD4 signalling pathways have been associated with the malignant behavior of esophageal adenocarcinoma (EAC). We recently developed two specific llama-derived antibodies (VHHs), C4C4 and C8C8, which target BMP4 and BMP2/4, respectively. Here we aimed to demonstrate the feasibility of the VHHs for the treatment of EAC and to elucidate its underlying mechanism. Methods Gene Set Enrichment Analysis (GSEA) was performed on a TCGA dataset, while expression of SHH, BMP2/4 and SMAD4 was validated in a cohort of EAC patients. The effects of the VHHs were tested on the recently established SMAD4(-) ISO76A primary EAC cell line and its counterpart SMAD4(+) ISO76A. In a patient-derived xenograft (PDX) model, the VHHs were evaluated for their ability to selectively target tumor cells and for their effects on tumor growth and survival. Results High expression of BMP2/4 was detected in all SMAD4 negative EACs. SHH upregulated BMP2/4 expression and induced p38 MAPK signaling in the SMAD4(-) ISO76A cells. Inhibition of BMP2/4 by VHHs decreased the aggressive and chemo-resistant phenotype of the SMAD4(-) ISO76A but not of the SMAD4(+) ISO76A cells. In the PDX model, in vivo imaging indicated that VHHs effectively targeted tumor cells. Both VHHs significantly inhibited tumor growth and acted synergistically with cisplatin. Furthermore, we found that C8C8 significantly improved survival of the mice. Conclusions Our data indicate that increased BMP2/4 expression triggers aggressive non-canonical BMP signaling in SMAD4 negative EAC. Inhibiting BMP2/4 decreases malignant behavior and improves survival. Therefore, VHHs directed against BMP2/4 hold promise for the treatment of SMAD4 negative EAC.